These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32771304)

  • 21. Interplay between SARS-CoV-2 and the type I interferon response.
    Sa Ribero M; Jouvenet N; Dreux M; Nisole S
    PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques.
    Shan C; Yao YF; Yang XL; Zhou YW; Gao G; Peng Y; Yang L; Hu X; Xiong J; Jiang RD; Zhang HJ; Gao XX; Peng C; Min J; Chen Y; Si HR; Wu J; Zhou P; Wang YY; Wei HP; Pang W; Hu ZF; Lv LB; Zheng YT; Shi ZL; Yuan ZM
    Cell Res; 2020 Aug; 30(8):670-677. PubMed ID: 32636454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological assessment of hospitalized patients with COVID-2019.
    Wölfel R; Corman VM; Guggemos W; Seilmaier M; Zange S; Müller MA; Niemeyer D; Jones TC; Vollmar P; Rothe C; Hoelscher M; Bleicker T; Brünink S; Schneider J; Ehmann R; Zwirglmaier K; Drosten C; Wendtner C
    Nature; 2020 May; 581(7809):465-469. PubMed ID: 32235945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of flavonoids against coronavirus infection.
    Russo M; Moccia S; Spagnuolo C; Tedesco I; Russo GL
    Chem Biol Interact; 2020 Sep; 328():109211. PubMed ID: 32735799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 27. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
    Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
    Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of RNA sequences of 3636 SARS-CoV-2 collected from 55 countries reveals selective sweep of one virus type.
    Biswas NK; Majumder PP
    Indian J Med Res; 2020 May; 151(5):450-458. PubMed ID: 32474553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection.
    Mohandas S; Jain R; Yadav PD; Shete-Aich A; Sarkale P; Kadam M; Kumar A; Deshpande G; Baradkar S; Patil S; Sapkal G; Mali D; Salve M; Patil D; Majumdar T; Suryawanshi A; Kaushal H; Lakra R; Dighe H; Gupta N; Abraham P; Gangakhedkar RR
    Indian J Med Res; 2020 May; 151(5):479-482. PubMed ID: 32611917
    [No Abstract]   [Full Text] [Related]  

  • 36. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
    Sarkar B; Ullah MA; Johora FT; Taniya MA; Araf Y
    Immunobiology; 2020 May; 225(3):151955. PubMed ID: 32517882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.
    Encinar JA; Menendez JA
    Viruses; 2020 May; 12(5):. PubMed ID: 32397643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibodies mediate virus-immune pathology of COVID-19.
    Jacobs JJL
    Med Hypotheses; 2020 Oct; 143():109884. PubMed ID: 32512289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.